Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Insulin Aspart Protamine, Human · Garzulys, Insulin Aspart Protamine And Insulin Aspart Mix 70/30

Recombinant protein · Agonist of insulin receptor (INSR) · developed by Novo Nordisk

Approved FDA, Jun 2000
1 Registered trials

What is Insulin Aspart Protamine, Human?

Insulin aspart protamine, human is a mixture of intermediate-acting insulin aspart protamine and rapid-acting insulin aspart, both human insulin analogs. Insulin acts on the insulin receptor to stimulate peripheral glucose uptake and inhibit hepatic glucose production, lowering blood glucose. It is used to improve glycemic control in diabetes mellitus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Garzulys, Insulin Aspart Protamine And Insulin Aspart Mix 70/30, Insulin Diluting Medium For Kirsty, Novolog Mix 70/30, B-28-ASP-INSULIN
Drug type
Recombinant protein
Targets
insulin receptor (INSR)
Mechanism
Agonist of insulin receptor (INSR)
Pathways
glucose uptake, hepatic glucose production inhibition, lipolysis inhibition, proteolysis inhibition, protein synthesis
Therapy area
Endocrine, Metabolic
Developer
Novo Nordisk Inc
In trials of
MNKD
FDA status
Approved as Garzulys, Insulin Aspart Protamine And Insulin Aspart Mix 70/30, Insulin Diluting Medium For Kirsty (June 7, 2000), BLA020986 · FDA label
UNII
D933668QVX

✅ FDA-approved uses

From the indications section of the FDA label (version of May 18, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00309244 Phase 3 Diabetes Type 2 Completed MNKD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetes Type 2

Other drugs acting on INSR

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.